CytoGenix, Inc. Anti-Sepsis Compound Works in Mice, Files U.S. Patent Application HOUSTON, April 6, 2004 (PRIMEZONE) -- CytoGenix, Inc. (OTCBB:CYGX) announces the filing of a patent application with the U.S. Patent and Trademark Office for an invention titled Oligodeoxynucleotide...

CytoGenix Awarded National Cancer Institute Research Grant for Pre-Clinical Animal Trials of Aerosol Delivered Gene Silencing Agent Against Lung Tumors HOUSTON, March 10, 2004 (PRIMEZONE) -- CytoGenix, Inc. (OTCBB:CYGX) announced that the National Cancer Institute (NCI) has awarded the company a research grant to fund the first phase of a project...

CytoGenix Awarded National Cancer Institute Research Grant for Pre-Clinical Animal Trials of Aerosol Delivered Gene Silencing Agent against Lung Tumors HOUSTON, March 9, 2004 (PRIMEZONE) -- CytoGenix, Inc. (OTCBB:CYGX) announced that the National Cancer Institute (NCI) has awarded the company a research grant to fund the first phase of a project...

CytoGenix Announces Results of Anti-Sepsis Pre-Clinical Animal Trials HOUSTON, March 2, 2004 (PRIMEZONE) -- CytoGenix, Inc. (OTCBB:CYGX) announced the successful completion of the first phase of pre-clinical animal studies. These proof-of-concept studies show that the...